MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14740338.2024.2392007

Медицинская библиотека · Expert opinion on drug safety · 2024

Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis.

Battista Teresa, Picone Vincenzo, Noto Matteo, Potestio Luca, Ruggiero Angelo, Martora Fabrizio, Megna Matteo, Genco Lucia

СтатьяОбзорСравнительное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Biological medications have significantly improved the prognosis of psoriasis patients. All biological drugs (except infliximab) for psoriasis require subcutaneous (SC) administration. Adverse events of biologic drug treatment include injection site reactions. ISRs are a local phenomenon characterized by swelling, erythema, pruritus, and pain around the injection site.

AREAS COVERED: We conducted a review to analyze the differences between the ISRs of various biologics approved for psoriasis. Specifically, the review focused on anti-TNF-α, anti-IL12/23, anti-IL-17, and anti-IL-23 drugs.

EXPERT OPINION: Etanercept and adalimumab have reported ISR rates of 37% and 20%, respectively, with erythema, pruritus, pain, and irritation being the most common. Citrate free (CF) solution and thinner needles have reduced ISR associated with adalimumab. Ustekinumab showed a low risk of ISR. Regarding secukinumab and ixekizumab, pain was found to be the most common ISR. The introduction of CF ixekizumab formulation has shown promise in reducing ISRs associated with ixekizumab. The risk of ISR appears insignificant with bimekizumab, brodalumab, and anti-IL23 drugs, with ISR rates ranging from less than 1% to 7.1%. The choice of biologic agent should consider ISR risk. Education on injection techniques and the use of single-dose autoinjectors/pens can mitigate ISR risk.

Для цитирования: Battista Teresa, Picone Vincenzo, Noto Matteo, Potestio Luca, Ruggiero Angelo, Martora Fabrizio, Megna Matteo, Genco Lucia. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis.. Expert opinion on drug safety. 2024. DOI: 10.1080/14740338.2024.2392007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.